Stanley G. Miele
Fondateur chez Aqualung Therapeutics Corp.
Profil
Stanley G.
Miele is the founder of Aqualung Therapeutics Corp.
founded in 2018, where he holds the title of President & Director.
He is currently the President of Sucampo Pharma Americas LLC since 2009.
Mr. Miele's former positions include National Sales Director-Cardiology at Millennium Pharmaceuticals, Inc. from 2003 to 2005, Sales Director at Abbott Point of Care, Inc. in 2006, and President, Senior VP-Sales & Marketing at Sucampo Pharmaceuticals, Inc. in 2011.
Mr. Miele received his undergraduate degree from the University of Dayton.
Postes actifs de Stanley G. Miele
| Sociétés | Poste | Début |
|---|---|---|
| Sucampo Pharma Americas LLC | President | 01/09/2009 |
Aqualung Therapeutics Corp.
 Aqualung Therapeutics Corp. BiotechnologyHealth Technology Aqualung Therapeutics Corp. is an early-stage biotech company based in Tucson, AZ. The private company is focused on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Aqualung Therapeutics is developing enamptor™, a next-gen platform comprised of a humanized enampt-neutralizing monoclonal antibody, a plasma-based biomarker panel, and a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of alt is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. Founded in 2016 by Stanley G. Miele and Joe G. N. Garcia, the company is led by Joe G. N. Garcia, who has been the CEO since incorporation. | Fondateur | 01/10/2018 |
Anciens postes connus de Stanley G. Miele
| Sociétés | Poste | Fin |
|---|---|---|
Abbott Point of Care, Inc.
 Abbott Point of Care, Inc. Medical SpecialtiesHealth Technology Abbott Point of Care, Inc. manufactures handheld blood analysers. The company is headquartered in Princeton, NJ. | Sales & Marketing | 01/02/2006 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Sales & Marketing | 01/09/2005 |
| SUCAMPO PHARMACEUTICALS, INC. | President | 08/01/2013 |
Formation de Stanley G. Miele
| University of Dayton | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Abbott Point of Care, Inc.
Abbott Point of Care, Inc. Medical SpecialtiesHealth Technology Abbott Point of Care, Inc. manufactures handheld blood analysers. The company is headquartered in Princeton, NJ. | Health Technology |
| Sucampo Pharma Americas LLC | |
Aqualung Therapeutics Corp.
Aqualung Therapeutics Corp. BiotechnologyHealth Technology Aqualung Therapeutics Corp. is an early-stage biotech company based in Tucson, AZ. The private company is focused on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Aqualung Therapeutics is developing enamptor™, a next-gen platform comprised of a humanized enampt-neutralizing monoclonal antibody, a plasma-based biomarker panel, and a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of alt is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. Founded in 2016 by Stanley G. Miele and Joe G. N. Garcia, the company is led by Joe G. N. Garcia, who has been the CEO since incorporation. | Health Technology |
